Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Intelligent Bio Solutions Inc. (INBS) registered 6,211,809 common shares for resale by selling stockholders, all issuable upon exercise of warrants from its September 2026 private placement. The shares comprise 2,036,659 under each of the Series M Pre-Funded, Series N-1 and Series N-2 Warrants, plus 101,832 under Placement Agent Warrants. The Series M, Series N-1 and Placement Agent Warrants are immediately exercisable; Series N-2 Warrants are exercisable after stockholder approval, which INBS agreed to seek at a meeting on or before December 31, 2026.
INBS receives no proceeds from resales, but may receive proceeds from cash warrant exercises and intends to use them for working capital and general corporate purposes. If all specified warrants are exercised for cash, the company estimates gross proceeds of approximately $9.82 million. INBS reported approximately $5.0 million in gross proceeds from the private placement, before fees and expenses and excluding warrant-exercise proceeds. The auditor's report on the incorporated financial statements includes an explanatory paragraph regarding the company's ability to continue as a going concern.
Intelligent Bio Solutions Inc. (INBS) is registering 6,211,809 shares of common stock on Form S-3 for resale by existing holders, all issuable upon exercise of outstanding warrants from a September 2026 private placement and related placement agent warrants. The company itself is not selling any shares in this offering and will not receive proceeds from resales; cash will go to the selling stockholders. INBS may receive up to approximately $9.82 million only if all registered warrants are exercised for cash, and it plans to use any such funds for working capital and general corporate purposes. As of September 14, 2026, 3,316,803 shares of common stock were outstanding, so the registered resale amount is large relative to the current share count, which the company notes could weigh on the trading price if sold rapidly. The prospectus highlights prior Nasdaq bid-price deficiency resolved via a December 2025 reverse stock split and notes that continued listing still depends on meeting ongoing Nasdaq requirements. The company’s auditor has included a going-concern explanatory paragraph in the latest annual financial statements, and the prospectus emphasizes extensive risk factors and forward‑looking statement cautions for prospective investors.
INTELLIGENT BIO SOLUTIONS INC. (INBS) filed a Form D for a new exempt private offering under Rule 506(b) of Regulation D, covering equity and warrants. The company reports that it has sold $4,979,631 of securities, with no remaining amount offered, and states the offering was closed on September 2, 2026 after a first sale on August 31, 2026.
Ladenburg Thalmann & Co. Inc. acted as placement agent, receiving $399,999.83 in commissions, a $49,999.98 management fee, $60,000 in expense reimbursement, and warrants for 101,832 shares of common stock, plus an ongoing 9% commission on gross proceeds from Series N-1 and N-2 warrant exercises. The issuer is a Delaware corporation in the health care biotechnology sector and declined to disclose its revenue range.
INTELLIGENT BIO SOLUTIONS INC. (INBS) reports an update to its capital structure. The company states that previously disclosed prefunded warrants were exercised for 285,000 shares of common stock, and 4,333 shares of restricted common stock were issued under an Investor Relations and Corporate Development Advisory Agreement. Following these issuances, the company reports that total outstanding common shares were 3,316,803 as of the close of business on September 10, 2026.
INTELLIGENT BIO SOLUTIONS INC. (INBS) reports that on September 9, 2026 it submitted a 510(k) premarket notification to the U.S. FDA, seeking regulatory clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The submission is based on a structured 2026 clinical program run with Cliantha Research and CenExel Clinical Research under FDA guidance and ICH GCP standards, including more than 18,000 hours of data collection, 18 detailed test reports, over 170 attachments and more than 15,000 lines of analyzed data.
A key Method Comparison Study showed accuracy above 98%, sensitivity above 94% and 100% specificity, with specimens verified by LC‑MS/MS. Additional usability, interference, precision, and cut-off studies, plus cybersecurity and software documentation resolving all 19 SBOM vulnerabilities and 100% of medium-risk issues, were included. The company frames this as supporting entry into the multi‑billion‑dollar U.S. drug screening market if FDA clearance is obtained, expanding its current non‑U.S. deployments.
Intelligent Bio Solutions Inc. (INBS) entered into a private placement with a single institutional investor involving 2,036,659 shares of common stock (or Series M pre-funded warrants in lieu) plus Series N-1 and Series N-2 warrants to purchase up to 2,036,659 shares each, at a combined price of $2.455 per unit, for gross proceeds of approximately $5.0 million before fees. At closing on September 2, 2026, all 2,036,659 units were issued as Pre-Funded Warrants instead of common stock.
Each Pre-Funded Warrant is exercisable for one share at $0.01 per share, and each Series N-1 and N-2 Warrant is exercisable for one share at $2.33 per share, with five-year terms starting when a resale registration statement is declared effective; N-2 warrants become exercisable only after shareholder approval. INBS agreed to file a resale registration statement for the shares and warrant shares by September 15, 2026 and to seek effectiveness by October 15, 2026, and will pay Ladenburg Thalmann a 9% total upfront fee on gross proceeds plus placement agent warrants for 101,833 shares at $3.06875 per share. The company expects to use net proceeds for working capital and general corporate purposes.
Intelligent Bio Solutions Inc. (INBS) reported new clinical performance data for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. In a multi-site U.S. Method Comparison Study, the System achieved overall 98.2% accuracy, 94.6% sensitivity, and 100% specificity across pre-employment and workplace screening settings.
The results, measured against a validated LC-MS/MS reference method, reflect an increase from a prior study that showed approximately 94% accuracy and 82% sensitivity, while maintaining 100% specificity. The company states these data complete the clinical component of its FDA 510(k) package and expects to submit its 510(k) application for the System in September 2026 as part of its planned entry into the U.S. market following FDA clearance.
INTELLIGENT BIO SOLUTIONS INC. (INBS) furnished an investor presentation under a Regulation FD current report. The company made a presentation about its business and operations available to investors on August 28, 2026, which can be accessed through the Investors section of its website.
The presentation is furnished, not filed, so it is not automatically incorporated into other Securities Exchange Act or Securities Act filings unless specifically referenced there.
Intelligent Bio Solutions Inc. (INBS) reported strong top-line growth for the full year ended June 30, 2026, while remaining significantly loss-making. Revenue reached $4.2 million, a 38% increase year-over-year, driven by a 22% rise in reader installed base to 1,886 units and a 35% increase in consumable cartridges to 106,500 units. Active customers grew to 502.
Gross profit rose to $2.05 million, up 64%, with gross margin expanding from 40.85% to 48.63%, helped by a manufacturing transition to Syrma Johari and a higher mix of cartridge consumables. Cash and cash equivalents increased to $3.99 million from $1.02 million, and total assets were $11.94 million with shareholders’ equity of $5.29 million.
Despite operating improvements, the business generated a sizeable net loss attributable to INBS of $12.43 million, compared with $10.57 million a year earlier, reflecting high selling, general and administrative plus development and regulatory expenses. The company advanced its FDA 510(k) program through multiple clinical, interference, precision, and usability studies and targets a submission in the second half of calendar 2026 to support planned U.S. market entry.